While Waiting for Valeant's 10-K, Five Questions for ManagementBy and
Company is restating 2014, 2015 results after investigation
CEO has been on extended medical leave since late December
When Valeant Pharmaceuticals International Inc. holds a conference call to discuss unaudited fourth-quarter results on Monday, investors will get the first substantial update on the drugmaker since Chief Executive Officer Michael Pearson went on indefinite medical leave in late December.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.